摘要
目的探讨依帕司他辅助治疗早期糖尿病肾病的临床效果。方法选取2017年10月~2018年10月我院收治的98例早期糖尿病肾病患者作为研究对象,采用随机数字表法将其分为实验组和对照组,每组各49例。两组患者均予以饮食控制、降糖降压等基础处理,对照组采用前列地尔注射液治疗,实验组患者则在此基础上加以依帕司他辅助治疗,两组患者均治疗12周。比较两组患者治疗前后的空腹血糖(FPG)、血肌酐(SCr)、尿素氮(BUN)、尿白蛋白排泄率(UAER)、β2微球蛋白(β2MG)水平及治疗总有效率。结果治疗前,两组的FPG、SCr、BUN、UAER、β2MG水平比较,差异无统计学意义(P>0.05);两组治疗后的FPG、SCr、BUN、UAER、β2MG水平均低于治疗前,差异有统计学意义(P<0.05);实验组治疗后的SCr、BUN、UAER、β2MG水平均低于对照组,差异有统计学意义(P<0.05);两组的FPG水平比较,差异无统计学意义(P>0.05)。实验组的治疗总有效率为93.88%,高于对照组的77.55%,差异有统计学意义(P<0.05)。结论早期糖尿病肾病患者应用依帕司他辅助治疗,能提高临床治疗效果,改善肾功能指标水平,值得临床推广应用。
Objective To explore the clinical effect of Epalrestat in the auxiliary treatment of early diabetic nephropathy.Methods A total of 98 patients with early diabetic nephropathy admitted to our hospital from October 2017 to October 2018 were selected as the research objects,they were divided into experimental group and control group by random number table method,each group had 49 cases.Both groups treated with diet control,blood glucose reduction and other basic treatment.The control group treated with Alprostadil Injection,the experimental group treated with Epalrestat auxiliary therapy on the basis of control group,both groups were treated for 12 weeks.The fasting blood glucose(FPG),serum creatinine(SCr),urea nitrogen(BUN),urinary albumin excretion rate(UAER)and β2-microglobulin(β2MG)levels before and after treatment and total effective rate of treatment were compared between the two groups.Results Before treatment,there were no significant differences in FPG,SCR,BUN,UAER and β2MG between the two groups(P>0.05).The levels of FPG,SCr,BUN,UAER and β2MG in the two groups were lower than those before treatment,the differences were statistically significant(P<0.05).The levels of SCr,BUN,UAER and β2MG in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in FPG levels between the two groups(P>0.05).The total effective rate of the experimental group was 93.88%,higher than 77.55% of the control group,the difference was statistically significant(P<0.05).Conclusion The application of Epalrestat in the treatment of early diabetic nephropathy can improve the effect of clinical treatment and the level of renal function index,which is worthy of clinical application.
作者
徐云发
刘晶
XU Yun-fa;LIU Jing(Department of Nephrology,the Second People′s Hospital of Yichun City,Jiangxi Province,Yichun 336000,China;Department of Endocrine,the Second People′s Hospital of Yichun City,Jiangxi Province,Yichun 336000,China)
出处
《中国当代医药》
2019年第34期56-58,共3页
China Modern Medicine
关键词
糖尿病肾病
依帕司他
辅助治疗
临床疗效
Diabetic nephropathy
Epalrestat
Auxiliary therapy
Clinical efficacy
